Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12560330 | 1.00 | CTSL (0.43) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL12560332 | 1.00 | CTSL (0.43) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL477845 | 0.82 | CTSL (0.49) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL16316719 | 0.82 | CTSL (0.49) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL477846 | 0.82 | CTSL (0.49) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL17802990 | 0.81 | AGTR2 (0.44) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL12559939 | 0.80 | GBA1 (0.42) | — | |
| SCHEMBL23294689 | 0.79 | CTSL (0.45) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL21390327 | 0.79 | CTSL (0.45) | CTSLCTSBCTSKTSHRAGTR2 | |
| SCHEMBL2933597 | 0.78 | TSHR (0.50) | CTSLCTSBCTSKTSHRAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PALANI ANANDAN | 2011-06-23 | — | — | US | disclosed |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-09 | — | — | US | disclosed |
| US-7750015-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7737155-B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | SCHERING CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019978-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | CTSL 2459/4885CTSB 2754/4885CTSK 2596/4885 |
| US-20070066630-A1 | Nitrogen-containing heterocyclic compounds and methods of use thereof | CYP11B2, CYP11B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CTSL 2259/4885CTSB 2899/4885CTSK 2618/4885 |
| US-20110152259-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | CTSL 2459/4885CTSB 2754/4885CTSK 2596/4885 |
| US-20100227873-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1 | CTSL 2459/4885CTSB 2754/4885CTSK 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.